



ASX ANNOUNCEMENT

12 November 2024

AGM Presentation and CEO Appointment

Sydney, Australia, 12 November 2024: Chimeric Therapeutics (ASX:CHM, “Chimeric” or the “Company”), an Australian leader in cell therapy, is pleased to provide the presentation to delivered at the Annual General Meeting to be held today.

When: 11:00 am AEDT, 12 November 2024

Where: Level 3, 62 Lygon Street, Carlton, Victoria 3053

Virtual: <https://web.lumiagm.com/323-551-853>

The presentation includes the appointment of Dr Rebecca McQualter as Chief Executive Officer effective today, and information under Listing Rule 3.16.4.

ABOUT CHIMERIC THERAPEUTICS

Chimeric Therapeutics, a clinical stage cell therapy company and an Australian leader in cell therapy, is focused on bringing the promise of cell therapy to life for more patients with cancer. To bring that promise to life for more patients, Chimeric’s world class team of cell therapy pioneers and experts is focused on the discovery, development, and commercialization of the most innovative and promising cell therapies.

Chimeric currently has a diversified portfolio that includes first in class autologous CAR T cell therapies and best in class allogeneic NK cell therapies. Chimeric assets are being developed across multiple different disease areas in oncology with 3 clinical stage programs.

CHM CDH17 is a first-in-class, 3rd generation CDH17 CAR T invented at the world-renowned cell therapy centre, the University of Pennsylvania (Penn) in the laboratory of Dr. Xianxin Hua, professor in the Department of Cancer Biology in the Abramson Family Cancer Research Institute at Penn. Preclinical evidence for CDH17 CAR T was published by Dr. Hua and his colleagues in March 2022 in Nature Cancer demonstrating complete eradication of tumours in 7 types of cancer in mice. CHM CDH17 is currently being studied in a phase 1/2 clinical trial in gastrointestinal and neuroendocrine tumours that was initiated in 2024.

CHM CLTX is a novel and promising CAR T therapy developed for the treatment of patients with



solid tumours. CLTX CAR T is currently being studied in a phase 1B clinical trial in recurrent / progressive glioblastoma. Positive preliminary data from the investigator-initiated phase 1A trial in glioblastoma was announced in October 2023.

CHM CORE-NK is a potentially best-in-class, clinically validated NK cell platform. Data from the complete phase 1A clinical trial was published in March 2022, demonstrating safety and efficacy in blood cancers and solid tumours. Based on the promising activity signal demonstrated in that trial, two additional Phase 1B clinical trials investigating CORE-NK in combination regimens have been initiated. From the CORE-NK platform, Chimeric has initiated development of new next generation NK and CAR NK assets.

Authorised on behalf of the Chimeric Therapeutics board of directors by Chairman Paul Hopper.

CONTACT

Investors

Dr Rebecca McQualter
Chief Operating Officer
Chimeric Therapeutics
T: +61 498 966 180
E: RMcQualter@chimerictherapeutics.com
W: www.chimerictherapeutics.com

Media

Matthew Wright
NWR Communications
P: +61 451 896 420
E: matt@nwrcommunications.com.au



CHIMERIC THERAPEUTICS

20
24

CHIMERIC

PIONEERS IN CELL THERAPY

Investor Update | 2024

ASX:
CHM

CHIMERIC THERAPEUTICS.COM



DISCLAIMER

Certain statements contained in this presentation, including, without limitation, statements containing the words "believes," "plans," "expects," "anticipates," and words of similar import, constitute "forward-looking statements." Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of Chimeric (collectively, "Chimeric" or the "Company") to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, among others, the following: the risk that our clinical trials will be delayed and not completed on a timely basis; the risk that the results from the clinical trials are not as favourable as we anticipate; the risk that our clinical trials will be more costly than anticipated; and the risk that

applicable regulatory authorities may ask for additional data, information or studies to be completed or provided prior to their approval of our products.

Given these uncertainties, undue reliance should not be placed on such forward-looking statements. The Company disclaims any obligation to update any such factors or to publicly announce the results of any revisions to any of the forward-looking statements contained herein to reflect future events or developments except as required by law.

This presentation may not contain all the details and information necessary for you to make a decision or evaluation. Neither this presentation nor any of its contents may be used for any other purpose without the prior written consent of the Company.



Dr Rebecca McQualter Appointed Chief Executive Officer



The Company is pleased to announce the appointment of current Chief Operating Officer, Dr Rebecca McQualter as Chief Executive Officer effective from 12 Nov 2024

For the purpose of ASX Listing Rule 3.16.4

Total Fixed Remuneration is A\$350,000 per annum, excluding statutory superannuation effective from 12 Nov 2024

All other terms of the employment agreement remain unchanged as previously disclosed in the Company's Annual Report for the year ended 30 June 2024 released on 21 October 2024.



CHIMERIC THERAPEUTICS

20
24

CHIMERIC

PIONEERS IN CELL THERAPY

Investor Update | 2024

ASX:
CHM

CHIMERIC THERAPEUTICS.COM




● ASX:CHM

CHM is a cancer cell therapy company with 3 CAR T & NK cell assets in 4 Phase 1/1b clinical trials



CAR-T CELL THERAPY EXPLAINED

Use a patient's own blood cells to make their individualised cancer therapy



Cell Therapy has been used for over 10 years in patients globally, with great success



Emily Whitehead more than a decade after first CAR-T treatment for blood cancer



CHM: BROAD PORTFOLIO

3 Novel cell therapies; 4 Clinical Trials

CHM CDH17

Technology from:



PHASE 1/2 TRIAL OPEN

Sarah Cannon Cancer Centre
UPenn Oncology

CHM CLTX

Technology from:



Phase 1A completed: COH

PHASE 1B TRIAL OPEN

Sarah Cannon Cancer Centre

CHM CORE-NK

Technology from:



**PHASE 1B
TRIAL OPEN**

MD Anderson

**PHASE 1B
TRIAL OPEN**

Case Western



CHM CORE NK + SOC

Ongoing Complete response in high risk blood cancer 48 months durability

PATIENT #8

33-year-old female

SITE: MDACC

DIAGNOSIS: Myeloid
Dysplastic Syndrome

HISTORY: Progressive
disease with prior
allogeneic transplant

SAFETY: No dose limiting
toxicities, no cytokine
release syndrome, no GvHD

CORE NK INFUSION

Patient Doses

COMPLETE RESPONSE

DAY 100

Enabling patient to
undergo transplant

STABLE DISEASE

DAY 28

ONGOING COMPLETE RESPONSE

48+ MONTHS

CR = no signs of cancer
in response to treatment



CHM CORE NK COMBINATION TRIAL

Complete response in high risk blood cancer combination trial

PATIENT #3
female

SITE: Case Western

DIAGNOSIS: Actue Myeloid
Dysplastic Syndrome

SAFETY: No dose limiting
toxicities, no cytokine
release syndrome, no GvHD

CORE NK
INFUSION + TGF-B

Day 1

**COMPLETE
RESPONSE**

DAY 28

CR = no signs of cancer
in response to treatment



MULTIPLE CLINICAL CATALYSTS IN THE NEXT 12MTHS

2023 Achievements and Deliverables in 2024

2023 Achievements

2024 Deliverables

CHM CDH17

- ✓ FDA IND Clearance for Ph. 1/2 Trial

- ✓ Ph. 1/2 Site Open
- ✓ 1st patient dosed
- 1st dose co-hort complete

CHM CLTX

- ✓ Ph. 1A trail complete in GBM
- ✓ Ph. 1A Positive Preliminary Data in GBM
- ✓ Ph. 1B 1st Patient Treated in GBM

- Ph. 1B new trial design
- Ph. 1B new trial implemented

CHM CORE-NK

- ✓ Ph. 1B ADVENT AML Site Initiation
- ✓ Ph. 1B CORE-NK 0201 + Vactosertib
1st Patient Treated

- ✓ Ph. 1B ADVENT AML 1st Patient Treated
- ✓ Ph. 1B ADVENT AML Dose Escalation
- Ph. 1B ADVENT AML Frontline
- Ph. 1B Advent AML Preliminary data



CHM LEADERSHIP TEAM

EXPERTS IN CELL THERAPY DEVELOPMENT & COMMERCIALISATION



Dr Rebecca McQUALTER
Chief Executive Officer



Dr Jason LITTEN
Chief Medical Officer



Dr Stephanie ASTROW
Chief Scientific Officer



Mr Kelly THORNBURG
VP Manufacturing

EXPERIENCE

75+

Years of Cell Therapy
Experience

EXPERTISE

50+

Development
Programs

RESULTS

5/6

FDA-Approved
CAR T Cell Therapies

AMGEN

Juno
THERAPEUTICS

Celgene

Kite

YESCARTA

TECARTUS

NOVARTIS

Fcete
THERAPEUTICS

artiva

KYMRIAH[®]
(tisagenlecleucel) Suspension
for IV infusion

Abecma

Breyanzi



INVESTMENT HIGHLIGHTS

4

4 Phase 1 clinical trials
under 3 FDA INDs at 4 leading US centres



Multiple clinical updates
in the next 12mths



Experienced leadership team
in cell therapy clinical development



CHM-CDH17
the ONLY CDH17 CAR-T in clinical trials



First in class
CLTX-CAR for brain cancer



Robust and long life
patent portfolio

CORPORATE PROFILE

Exchange	ASX: CHM
Share Price	\$0.01
52 Week Range	\$0.011- 0.047
Market Cap	~\$10M
Shares on issue	841M

IPO 2022

Major Shareholder **Paul Hopper 10.5%**

Effective 11.11.2024



CHIMERIC THERAPEUTICS

20
24

CHIMERIC

PIONEERS IN CELL THERAPY

Dr Rebecca McQualter
Chief Executive Officer
Chimeric Therapeutics Ltd
Melbourne, Australia
Tel: +61 498 966 180
investors@chimerictherapeutics.com